Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2

References

• Drucker D J, Ehrlich P, Asa S L, Brubaker P L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93: 7911–6
   PubMed Web of Science ®Google Scholar
• Lovshin J, Drucker D J. New frontiers in the biology of GLP-2. Regul Pept 2000; 90: 27–32
   PubMedGoogle Scholar
• Baksheev L, Fuller P J. Humoral factor in intestinal adaptation. Trends Endocrinol Metabol 2000; 11: 401–5
   PubMed Web of Science ®Google Scholar
• Jeppesen P B, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen B S, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in Short-Bowel patients with no colon. Gastroenterology 2001; 120: 806–15
   PubMed Web of Science ®Google Scholar
• Irwin D M, Huner O, Youson J H. Lamprey proglucagon and the origin of glucagon-like peptides. Mol Biol Evol 1999; 16: 1548–57
   PubMed Web of Science ®Google Scholar
• Hoyt E C, Lund P K, Winesett D E, Fuller C R, Ghatei M A, Bloom S R, et al. Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Diabetes 1996; 45: 434–9
   PubMed Web of Science ®Google Scholar
• Rouille Y, Martin S, Steiner D F. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 1995; 270: 26488–96
   PubMed Web of Science ®Google Scholar
• Scopsi L, Gullo M, Rilke F, Martin S, Steiner D F. Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab 1995; 80: 294–301
   PubMed Web of Science ®Google Scholar
• Rothenberg M E, Eilertson C D, Klein K, Zhou Y, Lindberg I, McDonald J K, et al. Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2, in vitro. J Biol Chem 1995; 270: 10136–46
   PubMed Web of Science ®Google Scholar
• Dhanvantari S, Seidah N G, Brubaker P L. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 1996; 10: 342–55
   PubMed Web of Science ®Google Scholar
• Dhanvantari S, Brubaker P L. Proglucagon processing in an islet cell line: effects of PCI overexpression and PC2 depletion. Endocrinology 1998; 139: 1630–7
   PubMed Web of Science ®Google Scholar
• Eissele R, Goke R, Willemer S, Harthus H P, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22: 283–91
   PubMed Web of Science ®Google Scholar
• Larsson L -I, Hoist J, Hakanson R, Sundler F. Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry 1975; 44: 281–90
   PubMedGoogle Scholar
• Brubaker P L, Izzo A, Hill M, Drucker D J. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol Endocrinol Metab 1997; 272: E1050–8
   PubMed Web of Science ®Google Scholar
• Fischer K D, Dhanvantari S, Drucker D J, Brubaker P L. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. Am J Physiol Endocrinol Metab 1997; 273: E815–20
   Web of Science ®Google Scholar
• Rocca A S, Brubaker P L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999; 140: 1687–94
   PubMed Web of Science ®Google Scholar
• Orskov C, Hoist J J, Knuhtsen S, Baldissera F GA, Poulsen S S, Nielsen O V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119: 1467–75
   PubMed Web of Science ®Google Scholar
• Xiao Q, Boushey R, Drucker D J, Brubaker P L. Secretion of the intestinotropic hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans. Gastroenterology 1999; 117: 99–105
   PubMed Web of Science ®Google Scholar
• Hartmann B, Johnsen A H, Orskov C, Adelhorst K, Thim L, Hoist J J. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000; 21: 73–80
   PubMed Web of Science ®Google Scholar
• Rocca A S, Brubaker P L. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology 1995; 136: 5593–9
   PubMed Web of Science ®Google Scholar
• Brubaker P L. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 1991; 128: 3175–82
   PubMed Web of Science ®Google Scholar
• Roberge J N, Brubaker P L. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993; 133: 233–40
   PubMed Web of Science ®Google Scholar
• Roberge J N, Gronau K A, Brubaker P L. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 1996; 137: 2383–8
   PubMed Web of Science ®Google Scholar
• Dumoulin V, Dakka T, Plaisancie P, Chayvialle J -A, Cuber J -C. Regulation of glucagon-like peptide-l-(7–36)amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 1995; 136: 5182–8
   PubMed Web of Science ®Google Scholar
• Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen P N, Hoist J J. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000; 280: E1010–8
   Google Scholar
• Rocca A S, LaGreca J, Kalitsky J, Brubaker P L. Mono-unsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology 2001; 42: 1148–55
   Google Scholar
• Tavares W, Drucker D J, Brubaker P L. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 2000; 278: E134–9
   PubMed Web of Science ®Google Scholar
• Hartmann B, Harr M B, Jeppesen P B, Wojdemann M, Deacon C F, Mortensen P B, et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000; 85: 2884–8
   PubMed Web of Science ®Google Scholar
• Drucker D J, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotech 1997; 15: 673–7
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9–24
   PubMed Web of Science ®Google Scholar
• Brubaker P L, Crivici A, Izzo A, Ehrlich P, Tsai C H, Drucker D J. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997; 138: 4837–43
   PubMed Web of Science ®Google Scholar
• Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotropic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 2000; 141: 4013–20
   PubMed Web of Science ®Google Scholar
• Xiao Q, Boushey R P, Cino M, Drucker D J, Brubaker P L. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 2000; 278: R1057–63
   Web of Science ®Google Scholar
• Dunphy J L, Justice F A, Taylor R G, Fuller P J. mRNA levels of dipeptidyl peptidase IV decrease during intestinal adaptation. J Surg Res 1999; 87: 130–3
   PubMed Web of Science ®Google Scholar
• Joseph J W, Kalitsky J, St-Pierre S, Brubaker P L. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic dbldb mice. Diahetologia 2000; 43: 1319–28
   PubMed Web of Science ®Google Scholar
• Gleeson M H, Bloom S R, Polak J M, Henry K, Dowling R H. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 1971; 12: 773–82
   PubMed Web of Science ®Google Scholar
• Stevens F M, Flanagan R W, O'Gorman D, Buchanan K D. Glucagonoma syndrome demonstrating giant duodenal villi. Gut 1984; 25: 784–91
   PubMed Web of Science ®Google Scholar
• Drucker D J, Yusta B, Boushey R P, DeForest L, Brubaker P L. Human (Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol Gastrointest Liver Physiol 1999; 276: G79–91
   PubMed Web of Science ®Google Scholar
• Tsai C H, Hill M, Drucker D J. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol Castrointest Liver Physiol 1997; 272: G662–8
   Web of Science ®Google Scholar
• Tsai C H, Hill M, Asa S L, Brubaker P L, Drucker D J. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol Endocrinol Metab 1997; 273: E77–84
   PubMed Web of Science ®Google Scholar
• Drucker D J, DeForest L, Brubaker P L. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol Castrointest Liver Physiol 1997; 273: G1252–62
   PubMed Web of Science ®Google Scholar
• Litvak D A, Hellmich M R, Evers M, Banker N A, Townsend C M, Jr. Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. J Gastroint Surg 1998; 2: 146–50
   PubMedGoogle Scholar
• Litvak D A, Evers B M, Hellmich M R, Townsend C M. Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin. J Castrointest Surg 1999; 3: 432–40
   PubMed Web of Science ®Google Scholar
• Kato Y, Yu D, Schwartz M Z. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 1999; 34: 18–21
   PubMed Web of Science ®Google Scholar
• Yusta B, Boushey R P, Drucker D J. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a PKA-independent pathway. J Biol Chem 2000; 275: 35345–52
   PubMed Web of Science ®Google Scholar
• Goodlad R A, Ghatei M A, Mandir N, Brynes A E, Jordinson M, Wright N A, et al. Glucagon-like peptide II (GLP-II) is trophic to the intestinal epithelium of intravenously and orally fed rats. Gastroenterology 1998; 114: A4695
   Web of Science ®Google Scholar
• Burrin D G, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington R K, et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Castrointest Liver Physiol 2000; 279: G1249–56
   PubMed Web of Science ®Google Scholar
• Lovshin J, Yusta B, Iliopoulos I, Migirdicyan A, Dableh L, Brubaker P L, et al. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology 2000; 141: 4194–201
   PubMed Web of Science ®Google Scholar
• Boushey R P, Tavares W, Yusta B, Koh T J, Wang T C, Drucker D J. Essential roles of the gastrin and glucagon genes in the response to experimental murine colitis. Gastroenterology 2000; 118: A4338
   Web of Science ®Google Scholar
• Kitchen P A, Fitzgerald A J, Goodlad R A, Barley N F, Ghatei M A, Legon S, et al. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. Am J Physiol Castrointest Liver Physiol 2000; 278: G425–8
   PubMed Web of Science ®Google Scholar
• Scott R B, Kirk D, MacNaughton W K, Meddings J B. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol Gastrointest Liver Physiol 1998; 275: G911–21
   Web of Science ®Google Scholar
• Cheeseman C I, Tsang R. The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol Gastrointest Liver Physiol 1996; 271: G477–82
   PubMed Web of Science ®Google Scholar
• Cheeseman C I. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol Regul Integr Comp Physiol 1997; 273: R1965–71
   PubMed Web of Science ®Google Scholar
• Benjamin M A, McKay D M, Yang P C, Cameron H, Perdue M H. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47: 112–9
   PubMed Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, Hoist J J. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand) Gastroenterol 1998; 33: 828–32
   PubMed Web of Science ®Google Scholar
• Bozkurt A, Naslund E, Hellstrom P M. Glp-1 and Glp-2 act in synergy to inhibit fasting small bowel motility in the rat. Gastroenterology 2000; 118: A3242
   Web of Science ®Google Scholar
• Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Hoist J J. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999; 84: 2513–7
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M, Larsen P J, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000; 6: 802–7
   PubMed Web of Science ®Google Scholar
• Munroe D G, Gupta A K, Kooshesh P, Vyas T B, Rizkalla G, Wang H, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96: 1569–73
   PubMed Web of Science ®Google Scholar
• Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119: 744–55
   PubMed Web of Science ®Google Scholar
• DaCambra M P, Yusta B, Sumner-Smith M, Crivici A, Brubaker P L. Structural determinants for activity of gluca-gon-like peptide-2. Biochemistry 2000; 39: 8888–94
   PubMed Web of Science ®Google Scholar
• Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, et al. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 1999; 274: 30459–67
   PubMed Web of Science ®Google Scholar
• Bloom S R, Polak J M. The hormonal pattern of intestinal adaptation: a major role for enteroglucagon. Scand J Gastroenterol 1982; 17(Suppl 74)93–103
   Google Scholar
• Thulesen J, Hartmann B, Nielsen C, Hoist J J, Poulsen S S. Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: effects of dietary fibre. Gut 1999; 45: 672–8
   PubMed Web of Science ®Google Scholar
• Jeppesen P B, Hartmann B, Thulesen J, Hansen B S, Hoist J J, Poulsen S S, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000; 47: 370–6
   PubMed Web of Science ®Google Scholar
• Sigalet D L, Martin G R. Hormonal therapy for short bowel. J Pediatr Surg 2000; 35: 360–4
   PubMed Web of Science ®Google Scholar
• Kato Y, Alavi K, Yu D, Schwartz M Z. Glucagon-like peptide-2 enhances intestinal function following massive small bowel resection. Gastroenterology 1998; 114: G4717
   Web of Science ®Google Scholar
• Thulesen J, Hartmann B, Kissow H, Jeppesen P B, Orskov C, Hoist J J, et al. Intestinal growth adaptation and glucagon-like peptide 2 (GLP-2) in plasma and intestinal tissue following small bowel resection or ileal-jejunal transposition in rats. Gastroenterology 2000; 118: A2912
   Web of Science ®Google Scholar
• Prasad R, Alavi K, Schwartz M Z. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 2000; 35: 357–9
   PubMed Web of Science ®Google Scholar
• Chance W T, Foley-Nelson T, Thomas I, Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Pbysiol 1997; 273: G559–63
   Web of Science ®Google Scholar
• Chance W T, Sheriff S, Foley-Nelson T, Thomas I, Balasubramaniam A. Maintaining gut integrity during parental nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer 2000; 37: 215–22
   PubMed Web of Science ®Google Scholar
• Boushey R P, Yusta B, Drucker D J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol Endocrinol Metab 1999; 277: E937–47
   Web of Science ®Google Scholar
• Tavakkolizadeh A, Shen R, Abraham P, Kormi N, Seifert P, Edelman E R, et al. Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis. J Surg Res 2000; 91: 77–82
   PubMed Web of Science ®Google Scholar
• Alavi K, Schwartz M Z, Palazzo J P, Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000; 35: 847–51
   PubMed Web of Science ®Google Scholar